/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES/
TORONTO, Sept. 20, 2018 /CNW/ - TerrAscend Corp. (CSE:TER) ("TerrAscend" or the "Company") today announced that the Company's wholly-owned subsidiary, Solace Health Network Inc. ("Solace Health Network"), has entered into an agreement with MCI Medical Clinics Inc. ("MCI") to provide medical cannabis services.
Solace Health Network is a medical education and support program with a focus on patient care through quality medical cannabis education, patient services and cannabinoid treatment plans. MCI is one of the largest primary medical care groups in Canada with twenty-six clinics located across the country with over two million registered patients.
"With Solace Health Network, patients have the option to meet with healthcare professionals and educators, either in-person or through a telehealth consultation from the convenience and privacy of a home environment." said Sabrina Ramkellawan, VP of Clinical Affairs at TerrAscend. "We have been working on numerous cannabinoid research initiatives with the goal of building a body of evidence to guide clinical education and support. With this agreement, these services will now be available to MCI patients at their clinic network."
Under the terms of the agreement, Solace Health Network will become the exclusive partner for MCI, providing MCI patients with access to expertise, services and information, as well as ongoing clinical and reimbursement support. Solace Health Network offers specialized services to meet the evolving needs of patients, including condition-specific treatment plans to assist patients with dose and strain selection as well as guidance through wellness plans for non-pharmacological treatments.
"On behalf of our expansive patient clinics throughout Alberta and Ontario, we are delighted to have selected Solace Health Network as our partner to serve patients with medical cannabis services" said Maddie Walker, President of MCI. "We are confident that their services of assessing, treating and managing patient needs for medical cannabis will provide an added and requested competency to our medical network."
About TerrAscend
TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. The Company provides support to medical consumers through its wholly-owned subsidiaries, Solace Health Inc., a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations and Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals.
Forward Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Although TerrAscend believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because TerrAscend can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release. TerrAscend undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of TerrAscend, its securities, or financial or operating results (as applicable). TerrAscend disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Related Link:
www.TerrAscend.com.
SOURCE TerrAscend
Gina DeBenedetti, VP, Communications, 1-855-TERRA-95 x100, [email protected]; Michael Nashat, President and CEO, 1-855 TERRA-95, [email protected]
Share this article